{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:17:04Z","timestamp":1783559824122,"version":"3.55.0"},"reference-count":81,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder clinically defined by cytopenias, bone marrow failure, and an increased risk of progressing to acute myeloid leukemia (AML). Traditionally, first-line treatment for patients with higher-risk MDS has been hypomethylating agents (HMAs). However, these agents have modest clinical activity as single agents. A one-size-fits-all treatment paradigm is insufficient for such a heterogeneous disease in the modern era of precision medicine. Several new agents have been developed for MDS with the hopes of improving clinical outcomes and survival. Pevonedistat is a first-in-class, novel inhibitor of neuronal precursor cell-expressed developmentally down-regulated protein-8 (NEDD8) activating enzyme (NAE) blocking the neddylation pathway leading to downstream effects on the ubiquitin\u2013proteosome pathway. Pevonedistat ultimately leads to apoptosis and inhibition of the cell cycle in cancer cells. Studies have demonstrated the safety profile of pevonedistat, leading to the development of multiple trials investigating combination strategies with pevonedistat in MDS and AML. In this review, we summarize the preclinical and clinical rationale for pevonedistat in MDS and AML, review the clinical data of this agent alone and in combination with HMAs to date, and highlight potential future directions for this agent in myeloid malignancies.<\/jats:p>","DOI":"10.1177\/20406207221112899","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T08:20:26Z","timestamp":1658478026000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?"],"prefix":"10.1177","volume":"13","author":[{"given":"Anson","family":"Snow","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine"},{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine"},{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, 170 Manning Drive, POB, 3rd Floor, CB #7305, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"bibr1-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.04.014"},{"key":"bibr2-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22570"},{"key":"bibr3-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.09.001"},{"key":"bibr4-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.02.029"},{"key":"bibr5-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01265-7"},{"key":"bibr6-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"bibr7-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000942"},{"key":"bibr8-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-453068"},{"key":"bibr9-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-496935"},{"key":"bibr10-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0085-4"},{"key":"bibr11-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100689"},{"key":"bibr12-20406207221112899","first-page":"397","volume":"12","author":"Mohammad AA.","year":"2018","journal-title":"Oncol Rev"},{"key":"bibr13-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25234"},{"key":"bibr14-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25950"},{"key":"bibr15-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"bibr16-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000127"},{"key":"bibr17-20406207221112899","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1210"},{"key":"bibr18-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0465"},{"key":"bibr19-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1349100"},{"key":"bibr20-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"bibr21-20406207221112899","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"L\u00fcbbert M","year":"2011","journal-title":"J Clin Oncol"},{"key":"bibr22-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6550"},{"key":"bibr23-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1021\/jm401856k"},{"key":"bibr24-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122980"},{"key":"bibr25-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8135"},{"key":"bibr26-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720955006"},{"key":"bibr27-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03380"},{"key":"bibr28-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn349"},{"key":"bibr29-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"bibr30-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518886"},{"key":"bibr31-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.336"},{"key":"bibr32-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1159\/000488712"},{"key":"bibr33-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.081"},{"key":"bibr34-20406207221112899","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00040"},{"key":"bibr35-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-403733"},{"key":"bibr36-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"bibr37-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206"},{"key":"bibr38-20406207221112899","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01751"},{"key":"bibr39-20406207221112899","volume":"165","author":"Francesca Ester M","year":"2016","journal-title":"Cell"},{"key":"bibr40-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1547"},{"key":"bibr41-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2018.01.009"},{"key":"bibr42-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3919"},{"key":"bibr43-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-016-0022-5"},{"key":"bibr44-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-1025-0_18"},{"key":"bibr45-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0979-1"},{"key":"bibr46-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.01.002"},{"key":"bibr47-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2009.12.024"},{"key":"bibr48-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/srep24218"},{"key":"bibr49-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0388"},{"key":"bibr50-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw209"},{"key":"bibr51-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254862"},{"key":"bibr52-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272567"},{"key":"bibr53-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.2988.2988"},{"key":"bibr54-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1414.1414"},{"key":"bibr55-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.658.658"},{"key":"bibr56-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13323"},{"key":"bibr57-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1338"},{"key":"bibr58-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1237"},{"key":"bibr59-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.578.578"},{"key":"bibr60-20406207221112899","first-page":"21","volume":"22","author":"Burton TR","year":"2003","journal-title":"Int J Oncol"},{"key":"bibr61-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-382226"},{"key":"bibr62-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.250"},{"key":"bibr63-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"bibr64-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01125-4"},{"key":"bibr65-20406207221112899","doi-asserted-by":"crossref","unstructured":"Zeidner JF, Mazerolle F, Bell JA, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine in higher-risk myelodysplastic syndromes\/chronic myelomonocytic leukemia or low-blast acute myeloid leukemia: exploratory analysis of patient-reported outcomes. In: Myelodysplastic syndromes \u2013 clinical studies: poster II: ASH, 6 December 2020, https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Session19866.html","DOI":"10.1182\/blood-2020-136935"},{"key":"bibr66-20406207221112899","volume":"324574","author":"Friedlander S","year":"2021","journal-title":"EHA Libr"},{"key":"bibr67-20406207221112899","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Girshova L, Doronin VA, et al. Pevonedistat (PEV)\u2009+\u2009azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)\/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20\u201330% marrow blasts: the randomized phase 3 PANTHER trial (NCT03268954). In: Myelodysplastic syndromes \u2013 clinical and epidemiological: treatment of high risk myelodysplastic syndrome oral: ASH, 11 December 2021, https:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper146154.html","DOI":"10.1182\/blood-2021-146154"},{"key":"bibr68-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.17"},{"key":"bibr69-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209608"},{"key":"bibr70-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"bibr71-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"bibr72-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401975"},{"key":"bibr73-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01614-z"},{"key":"bibr74-20406207221112899","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00645"},{"key":"bibr75-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1900"},{"key":"bibr76-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.74"},{"key":"bibr77-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.46"},{"key":"bibr78-20406207221112899","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3324\/haematol.2020.272609","volume":"107","author":"Cojocari D","year":"2022","journal-title":"Haematologica"},{"key":"bibr79-20406207221112899","unstructured":"Short NS, Bose P, DiNardo CD, et al. Preliminary results of a phase I\/II study of azacitidine, venetoclax and pevonedistat in patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy [EHA Library Short N 06\/12\/20; 294475; EP557], 2020, https:\/\/library.ehaweb.org\/pdfviewer\/web\/viewer.html?file=https%3A\/\/library.ehaweb.org\/eha\/download\/poster%3Fcm_id%3D298979"},{"key":"bibr80-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153682"},{"key":"bibr81-20406207221112899","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221112899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207221112899","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221112899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:16:15Z","timestamp":1777590975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207221112899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":81,"alternative-id":["10.1177\/20406207221112899"],"URL":"https:\/\/doi.org\/10.1177\/20406207221112899","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"20406207221112899"}}